Mounjaro's generic name is tirzepatide — here's what that means for you

Step 1, how a generic name is assigned and what it tells you

When a pharmaceutical company creates a new drug, regulators and the World Health Organisation assign it an International Non-proprietary Name (INN). That name belongs to the molecule, not the company. For this medicine, the INN is tirzepatide. Eli Lilly then chose Mounjaro as its trademark for the finished product sold in the UK and elsewhere.

The naming matters in practice. Your pharmacist's dispensing label, your GP's record, and every clinical study you read will use tirzepatide, the tirzepatide overview on this site explains the clinical evidence in full. When you search for trial results or NICE guidance, searching the generic name finds more than searching the brand. NICE's appraisal, for example, is formally titled "tirzepatide for managing overweight and obesity" (TA1026), even though the product it covers is sold as Mounjaro.

One practical note: the generic name does not mean there is a cheaper, unbranded version available. Unlike older medicines such as metformin or atorvastatin, tirzepatide is still under patent, there is no generic tirzepatide tablet or injection on the UK market. The branded KwikPen is the only licensed form.

Step 2, what tirzepatide actually does inside the body

Understanding the generic name also helps make sense of how the medicine works. Tirzepatide is a synthetic peptide that binds to two receptors: the glucose-dependent insulinotropic polypeptide receptor (GIP) and the glucagon-like peptide-1 receptor (GLP-1). Both are triggered by food, signalling fullness and influencing how the body manages blood sugar and energy storage.

Activating both pathways at once is what distinguishes tirzepatide from semaglutide, which targets GLP-1 alone. The clinical consequence was explored in the SURMOUNT-5 head-to-head trial (2025), which found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. The NHS covers both mechanisms on its tirzepatide medicines page, which is a useful plain-language read.

Treatment begins at a 2.5 mg dose, a starting point chosen to let the body adjust gradually, not a therapeutic target in itself. The prescriber titrates upward through 5, 7.5, 10, 12.5 and 15 mg based on how each dose is tolerated. That titration schedule is clinician-led; neither the brand name nor the generic name changes the fact that a prescriber steers it. Questions about the relationship between the generic and the brand come up often during consultations.

Step 3, the UK licence, regulatory status and what NICE says

Tirzepatide received its UK marketing authorisation under the Mounjaro brand. The licence covers weight management alongside a reduced-calorie diet and increased physical activity, for adults with a BMI of 30 or above, or 27 and above if at least one weight-related condition is present, conditions such as high blood pressure, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes.

The product also carries a Black Triangle (▼) designation, meaning the MHRA collects additional safety data as real-world use grows. That's standard for newer medicines, not a warning sign about tirzepatide specifically. You can report any suspected side effects via the MHRA Yellow Card scheme.

NICE recommended tirzepatide for NHS use in December 2024 (TA1026), initially for adults with a BMI of 35 or above plus at least one weight-related comorbidity. NHS rollout is phased and eligibility criteria are specific. Private prescribing through a regulated pharmacy is a parallel route for those who don't meet the NHS thresholds or prefer not to wait. If you're curious about how the name appears on prescriptions, or want to understand what 'generic Mounjaro' actually means in a UK context, those pages cover the detail.

Step 4, tirzepatide, cost context and choosing a regulated route

Because tirzepatide is still patented, the only version available in the UK is the Eli Lilly product sold as Mounjaro. Eli Lilly increased its UK list price substantially from September 2025, the highest dose moved from roughly £122 to around £330 per four-week pen, as widely reported. Private providers price differently, typically in the range of £149–£375 per month depending on dose and service.

For a full picture of how private pricing works (and what a legitimate price should include) the Lilly price increase explainer is worth reading before you compare providers. Our treatment page shows current pricing and what's included with a nume consultation.

One thing that doesn't change with any pricing structure: tirzepatide is a prescription-only medicine. Sellers offering it without a clinical assessment (regardless of what they call it, generic name or brand) are operating outside UK law. The pen in your fridge door should come with a dispensing label showing your name, the prescriber's name, and a GPhC-registered pharmacy.